NorthStrive Biosciences Updates Licensing Agreement with MOA Life Plus
PMGC Holdings Inc.’s subsidiary, NorthStrive Biosciences, announced a third amendment to its existing License Agreement with MOA Life Plus Co., Ltd., a Korean biotechnology company listed on KOSDAQ as 142760, on March 27, 2026, according to GlobeNewswire PE. The amendment specifically updates the timing and key development milestones for the human clinical development programs of EL-32 and EL-22.
Details of the Amendment
The updated agreement aligns the schedule for EL-32 and EL-22 with the parties’ research and development and regulatory expectations, as stated in the announcement. NorthStrive Biosciences holds the assets EL-32 and EL-22 under this License Agreement, which focuses on dual myostatin assets targeting muscle preservation in combination with GLP-1 treatments.
Company Backgrounds
MOA Life Plus Co., Ltd. is a Korean biotechnology company focused on the research, development, and commercialization of innovative therapeutic and wellness technologies, including global partnerships for human and animal health applications, according to GlobeNewswire PE. NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., is a biopharmaceutical company that develops and acquires cutting-edge aesthetic medicines, with EL-22 as its lead asset addressing muscle preservation in obesity treatments, including GLP-1 receptor agonists. PMGC Holdings Inc., listed on NASDAQ as ELAB, is a diversified holding company that manages its portfolio through strategic acquisitions and investments across various industries.
Implications in Context
While widely known that biotechnology firms like MOA Life Plus engage in licensing agreements to advance drug development, this amendment reflects ongoing efforts in the sector to align milestones with regulatory needs, as per the press release from GlobeNewswire PE.
